| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/MP.2011.131 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/mp.2011.131 |
| P932 | PMC publication ID | 3526727 |
| P698 | PubMed publication ID | 22024767 |
| P5875 | ResearchGate publication ID | 232776321 |
| P50 | author | Yunping Qiu | Q47229874 |
| Jingqin Wu | Q56845640 | ||
| Wei Jia | Q59677087 | ||
| P2093 | author name string | X Wang | |
| Y Cao | |||
| J Yang | |||
| L He | |||
| P Wang | |||
| T Chen | |||
| L Sun | |||
| Z Zhao | |||
| X Qi | |||
| K Zhou | |||
| P Yang | |||
| G Feng | |||
| M Su | |||
| A Zhao | |||
| C Wan | |||
| P2860 | cites work | alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population | Q21136353 |
| A systematic review of the prevalence of schizophrenia | Q21144720 | ||
| Abnormal glucose metabolism in the mediodorsal nucleus of the thalamus in schizophrenia | Q44750281 | ||
| Discovery of metabolomics biomarkers for early detection of nephrotoxicity | Q46043673 | ||
| Relative glucose metabolic rate higher in white matter in patients with schizophrenia | Q48118678 | ||
| Positron emission tomography studies of abnormal glucose metabolism in schizophrenia | Q48404768 | ||
| The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. | Q48468665 | ||
| High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. | Q48933956 | ||
| Metabolic profiling of plasma from discordant schizophrenia twins: correlation between lipid signals and global functioning in female schizophrenia patients. | Q51811350 | ||
| A strategy for identifying differences in large series of metabolomic samples analyzed by GC/MS. | Q52001513 | ||
| Glucose-induced increase in memory performance in patients with schizophrenia. | Q52032929 | ||
| Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis | Q55969864 | ||
| The use of the area under the ROC curve in the evaluation of machine learning algorithms | Q56594447 | ||
| Physiological and pathophysiological roles of excitatory amino acids during central nervous system development | Q68466342 | ||
| Schizophrenia: a biochemical disorder? | Q71233713 | ||
| Schizophrenia | Q79226206 | ||
| Niacin skin flushing in schizophrenic and depressed patients and healthy controls | Q79890673 | ||
| Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia | Q80024902 | ||
| Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia | Q21562668 | ||
| Common variants conferring risk of schizophrenia | Q24614376 | ||
| Common variants on chromosome 6p22.1 are associated with schizophrenia | Q24641881 | ||
| Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression | Q24654019 | ||
| Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis | Q28237307 | ||
| Common polygenic variation contributes to risk of schizophrenia and bipolar disorder | Q28250609 | ||
| Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress | Q28257571 | ||
| Transport of glutamate and other amino acids at the blood-brain barrier | Q28374449 | ||
| Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia | Q28469040 | ||
| CSF metabolic and proteomic profiles in patients prodromal for psychosis | Q28469277 | ||
| Reactive oxygen species: metabolism, oxidative stress, and signal transduction | Q29547615 | ||
| 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data | Q29784220 | ||
| High-throughput data analysis for detecting and identifying differences between samples in GC/MS-based metabolomic analyses | Q31002172 | ||
| Neuroimaging in psychiatry: An update | Q31057467 | ||
| The estrogen hypothesis of schizophrenia implicates glucose metabolism: association study in three independent samples | Q33332023 | ||
| Advances in proximal fluid proteomics for disease biomarker discovery | Q33731966 | ||
| Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms | Q34153146 | ||
| Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. | Q34192207 | ||
| Metabolomic mapping of atypical antipsychotic effects in schizophrenia. | Q34620002 | ||
| Glutathione pathways in the brain. | Q35129250 | ||
| Metabolic changes in schizophrenia and human brain evolution | Q36955023 | ||
| What we know: findings that every theory of schizophrenia should explain. | Q37159625 | ||
| Metabolic profile of antipsychotic-naive individuals with non-affective psychosis | Q37245422 | ||
| Metabolomics: a global biochemical approach to the study of central nervous system diseases | Q37289766 | ||
| Metabolomics tools for identifying biomarkers for neuropsychiatric diseases | Q37419784 | ||
| Nuclear magnetic resonance spectroscopy-based metabolomics of the fatty pancreas: implicating fat in pancreatic pathology | Q37466922 | ||
| The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics | Q37776737 | ||
| Metabolism of Ketone Bodies by the Brain | Q39927355 | ||
| Decreased rate of glucose utilization by rat brain in vivo after exposure to atmospheres containing high concentrations of CO2 | Q39963377 | ||
| Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. | Q43292555 | ||
| Fatty acid compositions of red blood cell phospholipids in children with autism | Q43621448 | ||
| The niacin skin flush test in schizophrenia: a replication study | Q43704551 | ||
| Cerebral cystine uptake: a tale of two transporters | Q44064852 | ||
| Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia | Q44299748 | ||
| Increased phospholipase A2 activity in schizophrenia with absent response to niacin | Q44369824 | ||
| Proteomics: advances in biomarker discovery | Q44597113 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 67-78 | |
| P577 | publication date | 2011-10-25 | |
| P1433 | published in | Molecular Psychiatry | Q6895973 |
| P1476 | title | Potential metabolite markers of schizophrenia | |
| P478 | volume | 18 |
| Q50663896 | 2,4-Dihydroxypyrimidine is a potential urinary metabolite biomarker for diagnosing bipolar disorder. |
| Q48050618 | A Novel Urinary Metabolite Signature for Non-invasive Post-stroke Depression Diagnosis |
| Q37235856 | A combined metabonomic and proteomic approach identifies frontal cortex changes in a chronic phencyclidine rat model in relation to human schizophrenia brain pathology |
| Q26765408 | A momentary biomarker for depressive mood |
| Q33575018 | A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study |
| Q93167649 | Age-specific urinary metabolite signatures and functions in patients with major depressive disorder |
| Q60311366 | Allopregnanolone Treatment Improves Plasma Metabolomic Profile Associated with GABA Metabolism in Fragile X-Associated Tremor/Ataxia Syndrome: a Pilot Study |
| Q34727281 | Altered coupling of regional cerebral blood flow and brain temperature in schizophrenia compared with bipolar disorder and healthy subjects |
| Q38226316 | Carbonyl stress and schizophrenia |
| Q30854785 | Changes in retinal metabolic profiles associated with form deprivation myopia development in guinea pigs |
| Q58302865 | Cognition, psychosis risk and metabolic measures in two adolescent birth cohorts |
| Q37733240 | Combined application of NMR- and GC-MS-based metabonomics yields a superior urinary biomarker panel for bipolar disorder. |
| Q36548377 | Comparative Circadian Metabolomics Reveal Differential Effects of Nutritional Challenge in the Serum and Liver |
| Q35683830 | Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial |
| Q30370117 | Cytosolic Accumulation of L-Proline Disrupts GABA-Ergic Transmission through GAD Blockade |
| Q38830302 | Discriminating poststroke depression from stroke by nuclear magnetic resonance spectroscopy-based metabonomic analysis |
| Q90049390 | Dysregulation of amino acids and lipids metabolism in schizophrenia with violence |
| Q34113374 | Evidence for disturbed insulin and growth hormone signaling as potential risk factors in the development of schizophrenia |
| Q41628681 | Fusing Sensor Paradigms to Acquire Chemical Information: An Integrative Role for Smart Biopolymeric Hydrogels. |
| Q57161916 | GC-MS-based metabolomics approach to diagnose depression in hepatitis B virus-infected patients with middle or old age |
| Q36508139 | Identification and validation of urinary metabolite biomarkers for major depressive disorder |
| Q42257121 | Identification of a plasma signature of psychotic disorder in children and adolescents from the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort. |
| Q37648213 | Identification of sex-specific urinary biomarkers for major depressive disorder by combined application of NMR- and GC-MS-based metabonomics |
| Q47587418 | Identification of the Niacin-Blunted Subgroup of Schizophrenia Patients from Mood Disorders and Healthy Individuals in Chinese Population |
| Q34048645 | Impaired metabolic reactivity to oxidative stress in early psychosis patients |
| Q50598719 | Increased serum fibroblast growth factor 21 levels in patients with schizophrenia. |
| Q30422062 | Inflammation and the two-hit hypothesis of schizophrenia |
| Q63433311 | Integrated Lipidomics and Proteomics Point to Early Blood-Based Changes in Childhood Preceding Later Development of Psychotic Experiences: Evidence From the Avon Longitudinal Study of Parents and Children |
| Q33945211 | Integrative proteomic analysis of the NMDA NR1 knockdown mouse model reveals effects on central and peripheral pathways associated with schizophrenia and autism spectrum disorders |
| Q26771434 | Making Sense of Blood-Based Proteomics and Metabolomics in Psychiatric Research |
| Q89183179 | Mega-analysis of Odds Ratio: A Convergent Method for a Deep Understanding of the Genetic Evidence in Schizophrenia |
| Q35200833 | Metabolite profiling in posttraumatic stress disorder |
| Q36930380 | Metabolomic Analysis in Brain Research: Opportunities and Challenges |
| Q94560673 | Metabolomic Profiling Revealed Potential Biomarkers in Patients With Moyamoya Disease |
| Q36743314 | Metabolomic Profiling of Post-Mortem Brain Reveals Changes in Amino Acid and Glucose Metabolism in Mental Illness Compared with Controls |
| Q35829940 | Metabolomics Approach Reveals Integrated Metabolic Network Associated with Serotonin Deficiency |
| Q90341474 | Metabolomics Biomarkers for Precision Psychiatry |
| Q49243371 | Metabolomics diagnostic approach to mustard airway diseases: a preliminary study. |
| Q44951888 | Metabolomics for the masses: The future of metabolomics in a personalized world |
| Q38051186 | Metabolomics: a novel approach to identify potential diagnostic biomarkers and pathogenesis in Alzheimer's disease |
| Q52316654 | Mitochondrial function in individuals at clinical high risk for psychosis. |
| Q37721268 | Modified Mediterranean Diet for Enrichment of Short Chain Fatty Acids: Potential Adjunctive Therapeutic to Target Immune and Metabolic Dysfunction in Schizophrenia? |
| Q47112971 | Neural-specific deletion of mitochondrial p32/C1qbp leads to leukoencephalopathy due to undifferentiated oligodendrocyte and axon degeneration |
| Q33704082 | Novel urinary metabolite signature for diagnosing postpartum depression |
| Q27011617 | Obesity and psychotic disorders: uncovering common mechanisms through metabolomics |
| Q64060695 | Objective diagnosis of post-stroke depression using NMR-based plasma metabonomics |
| Q26784904 | Omics-Based Biomarkers: Application of Metabolomics in Neuropsychiatric Disorders |
| Q95579807 | Opportunities and challenges in psychopharmacology |
| Q98611576 | Peripheral serum metabolomic profiles inform central cognitive impairment |
| Q88982667 | Pharmacotherapy of schizophrenia: toward a metabolomic-based approach |
| Q35845210 | Plasma Metabolic Profiles in Women are Menopause Dependent |
| Q124094899 | Plasma metabolic alterations and potential biomarkers in individuals at clinical high risk for psychosis |
| Q35816838 | Potential of serum metabolites for diagnosing post-stroke cognitive impairment |
| Q36395466 | Potential serum biomarkers from a metabolomics study of autism |
| Q33863985 | Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients |
| Q36676574 | Random forest in clinical metabolomics for phenotypic discrimination and biomarker selection |
| Q30874878 | Reconstruction and analysis of correlation networks based on GC-MS metabolomics data for young hypertensive men. |
| Q89867510 | Redox Is a Global Biodevice Information Processing Modality |
| Q35952743 | Relationship between Erythrocyte Fatty Acid Composition and Psychopathology in the Vienna Omega-3 Study |
| Q38324251 | Schizophrenia biomarkers: translating the descriptive into the diagnostic |
| Q36203421 | Schizophrenia shows a unique metabolomics signature in plasma |
| Q48048867 | Seeking an objective diagnosis of depression |
| Q41197076 | Serum fatty acid patterns in patients with schizophrenia: a targeted metabonomics study |
| Q55082720 | Serum levels of β-hydroxybutyrate and pyruvate, metabolic changes and cognitive function in patients with schizophrenia during antipsychotic treatment: a preliminary study. |
| Q36146659 | Serum trace element differences between Schizophrenia patients and controls in the Han Chinese population |
| Q34757521 | Sex-specific urinary biomarkers for diagnosing bipolar disorder |
| Q41791000 | Short overview on metabolomic approach and redox changes in psychiatric disorders. |
| Q92783462 | Systematic impacts of chronic unpredictable mild stress on metabolomics in rats |
| Q36785265 | The Brain Metabolome of Male Rats across the Lifespan. |
| Q38006632 | The emerging spectrum of allelic variation in schizophrenia: current evidence and strategies for the identification and functional characterization of common and rare variants |
| Q61798989 | The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice |
| Q33679513 | The potential biomarker panels for identification of Major Depressive Disorder (MDD) patients with and without early life stress (ELS) by metabonomic analysis |
| Q64944036 | Therapeutic Potential of Exogenous Ketone Supplement Induced Ketosis in the Treatment of Psychiatric Disorders: Review of Current Literature. |
| Q97423833 | Topology predicts long-term functional outcome in early psychosis |
| Q98158696 | Ubiquitin-proteasome system, lipid metabolism and DNA damage repair are triggered by antipsychotic medication in human oligodendrocytes: implications in schizophrenia |
| Q91973058 | Urinary Amine and Organic Acid Metabolites Evaluated as Markers for Childhood Aggression: The ACTION Biomarker Study |
| Q26769944 | Urinary Biomarkers of Brain Diseases |
| Q57155162 | Urinary biomarker panel for diagnosing patients with depression and anxiety disorders |
| Q35645024 | Urinary metabonomics for diagnosis of depression in hepatitis B virus-infected patients |
Search more.